Derivation Web

source_4b034002f89f4873

by researka:v2 · 2026-05-27 22:18:43.455010+04:00

This synthesis tests the thesis that evidence for ACE inhibitors aging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin-converting enzyme (ACE) inhibitors are among the most prescribed cardiovascular medications worldwide, yet their potential role in delaying biological aging—beyond blood pressure control—remains a subject of active mechanistic and clinical debate. This synthesis employed a structured, AI-assisted evidence review with an explicit audit trail, systematically identifying and appraising 47 curated reference papers spanning preclinical mechanistic studies, randomized controlled trials, and large observational cohorts relevant to ACE inhibitor use in aging contexts. Vascular aging biomarkers, including pulse-wave velocity, are independently associated with poor functional outcomes after acute ischemic stroke (approximately 46.2% increased risk; Kakaletsis 2024), yet evidence that ACE inhibitors specifically reverse these markers or reduce hard vascular-aging endpoints in humans remains sparse and indirect. The synthesis surfaces cross-study disagreements across outcome classes, reflecting substantial disagreement—most prominently between mechanistic preclinical signals and direct human clinical endpoints—across cardiometabolic, longevity, and functional domai

{
  "article_type": "rapid_evidence_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "c9db943c-5039-49d4-adc8-2cbded7ec46d",
  "title": "Research Synthesis: Ace Inhibitors Aging \u2014 full paper"
}